ANTIGENIC AND PROTECTIVE PROPERTIES OF EXPERIMENTAL ASSOCIATED VIRUS VACCINE AGAINST SHEEP POX AND GOAT POX

Studies have been carried on antigenic and protective activity of the experimental associated vaccine containing, in the field vaccination dose, antigens of the attenuated ARRIAH strain of the sheep pox virus and ARRIAH 2003 strain of the goat pox virus in the ratio of 4.24 and 4.24 lg TCD₅₀/cm³, 4.18 and 4.37 lg TCD₅₀/cm³ and 4.37 and 4.18 lg TCD₅₀/cm³ respectively, as well as monovalent vaccines with the infectious activity of these strains with a titer of 4.5 lg TCD₅₀/cm³. Administration of the associated virus vaccine did not adversely affect the physiological state of the animals and was accompanied by the formation of viral neutralizing antibodies in protective titres that did not differ from antibody titers in the blood of sheep and goats during monovalent immunization. High levels of virus neutralizing antibodies in the range of (3.50 ± 0.50)–(4.05 ± 0.22) and (3.58 ± 0.08)–(4.00 ± 0.29) log₂ respectively were determined in the blood serum of all sheep and goats vaccinated with associated vaccines. The antigenic activity of the associated vaccines for goats and sheep is almost identical. There were no negative effects on the antigenic activity of different ratios of attenuated strains of the sheep pox and goat pox virus in the inoculation dose. All sheep immunized with the monovalent vaccine against sheep and goat pox and associated virus vaccines, resisted the disease when challenged with a virulent sheep pox virus “Afghanistan” strain. Three sheep vaccinated with a monovalent vaccine against goat pox demonstrated a large local reaction, one sheep was diagnosed with generalized form of sheep pox.

1. Bakulov I. A., Balyshev V. М., Selyaninov Yu. O. et al. Biological properties of experimental associated vaccine against anthrax and sheep pox [Biologicheskie svoj stva eksperimental’noj associirovannoj vakciny protiv sibirskoj jazvy i ospy ovec]. Veterinariya. 2001; 1: 39–41 (in Russian).

2. Diev V. I., Starov S. K., Basova D. K. et al. Experimental study of efficacy of poxvirus vaccine administered to sheep under epidemic conditions [Izuchenie effektivnosti virusvakciny protiv ospy na ovcah v eksperimental’nyh uslovijah i uslovijah epizootii]. Veterinary Science Today. 2017; 2: 62–66 (in Russian).

3. Parilov S. V., Knize A. V., Balyshev V. M. Analysis and predictions of global epidemic situation for sheep and goat pox and PPR in 2011–2015 [Analiz i prognoz mirovoj epizooticheskoj situacii po ospe ovec i koz i chumy melkih zhvachnyh zhivotnyh v 2011–2015 gg.]. Nauchnyj zhurnal KubGAU. 2011; 69. URL: http://ej.kubagro.ru/2011/05/pdf/21.pdf (in Russian).

4. Piskunov А. V., Kononov А. V., Sprygin А. V. et al. Predictions for sheep and goat pox in the Russian Federation in 2018 [Prognoz po ospe ovec i koz v Rossijskoj Federacii na 2018 god]. Prognozy po zaraznym boleznyam zhivotnyh v Rossijskoj Federacii na 2018 god. FGBI “ARRIAH”. Vladimir, 2018: 186–195 (in Russian).

5. Kurchenko F. P., Ulasov V. I., Diev V. I. et al. Standardization of immunogenicity control method for sheep and goat poxvirus vaccine [Standartizacija metoda kontrolja immunogennosti virusvakciny protiv ospy ovec i koz]. Veterinariya. 2006; 10: 22–24 (in Russian).

6. Hosomani M., Kumar Singh S., Mondal B. et al. A bivalent vaccine against goat pox and peste des petits ruminants induces protective immune response in goats. Vaccine. 2006; 24 (35–36): 6058–6064.

7. Chen W., Hu S., Qu L. et al. A goat poxvirus-vectored peste-des-petits-ruminants vaccine induces long-lasting neutralization antibody to high levels in goats and sheep, Vaccine. 2010; 28 (30): 4742–4750.

8. Barman D., Chatterjee A., Guha C. et al. Estimation of post-vaccination antibody titre against goat pox and determination оf protective antibody titre. Small Ruminant Res. 2010; 93: 76–78.

9. Sheep pox and goat pox // OIE. Manual of Diagnostic Tests and Vaccines for Terrestrial Animals (mammals, birds and bees). 2017; 2, (2.7.13). URL: http://www.oie.int/fileadmin/Home/eng/Health_standards/tahm/2.07.13_S_POX_G_POX.pdf.